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dase relative to the parental cells. To combat increases
in oxidative stress caused by A, it is necessary for the
cell to produce increased amounts of molecules having
a high transfer potential such as reduced nicotinamide
adenine dinucleotide phosphate (NADPH) and nicotin-
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equivalents is best achieved via glycolysis to produce
NADH and by the hexose monophosphate shunt (HMS)
to produce NADPH. Changes in glucose metabolismSummary
are associated with AD (Mielke et al., 1991), and the
upregulation of glucose metabolism is tied to the activa-It is frequently argued that both amyloid beta (A) and
oxidative stress are involved in the pathogenesis of tion of the transcription factor HIF-1 (Semenza, 1999).
HIF-1 is a heterodimeric transcription factor com-Alzheimer’s disease (AD). We show here that clonal
nerve cell lines and primary cortical neurons that are prised of two subunits, HIF-1 and HIF-1 (Wang et al.,
1995). Under normoxic conditions, HIF-1 DNA bindingresistant to A toxicity have an enhanced flux of glu-
cose through both the glycolytic pathway and the hex- and transcription of hypoxia-inducible genes does not
occur. Because oxygen and iron are required for theose monophosphate shunt. AD brain also has in-
creased enzymatic activities in both pathways relative inhibition of HIF-1 activity, iron chelators can mimic hyp-
oxia and induce HIF-1. HIF-1 mediates the adaptationto age-matched controls. The A-induced changes in
glucose metabolism are due to the activation of the of cells to hypoxia and hypoglycemia by upregulating
the expression of genes involved in erythropoiesis, angi-transcription factor hypoxia inducible factor 1 (HIF-1).
As a result of A-induced changes in glucose metabo- ogenesis, glucose transport, and glycolysis (Semenza,
1999). Cells that make more use of glycolysis than oxida-lism, A-resistant cells are more readily killed by glu-
cose starvation and by classes of antipsychotic drugs tive phosphorylation to meet their energy demands tend
to lower the mitochondrial production of ROS (Brand,that inhibit glucose uptake.
1997).
Two observations suggested that HIF-1 activity mayIntroduction
be involved in protecting cells from A neurotoxicity.
Iron chelators and heat shock protect cells from AAlzheimer’s disease (AD) is characterized by extensive
cell death within the brain (Terry et al., 1994). However, toxicity (Behl and Schubert, 1993; Schubert and Chev-
ion, 1995), and both conditions induce HIF-1 activityas with most other neurobiological diseases, not all of
the cells within an afflicted area die. There appear to be (Katschinski et al., 2002). It was therefore asked if HIF-1
activity is the mechanism used to regulate the A-populations of cells which survive the same conditions
that kill their neighbors. Although there has been intense induced changes in glucose metabolism. The data pre-
sented below show that glycolysis, the HMS, and glu-interest in the mechanisms of cell death, very few stud-
ies have attempted to understand how nerve cells be- cose uptake are upregulated in the A-resistant cells
as well as in cortical neurons exposed to subtoxic levelscome resistant to potential toxins or loss of trophic sup-
port. In the case of AD, many believe that the A peptide of A, and that glycolytic and HMS enzymes are more
active in lysates of AD brain compared to age-matchedis the primary toxic agent responsible for nerve cell
death (Klein et al., 2001). Therefore, by examining how controls. The enhanced glycolysis in the cultured cells
is due to the activation of HIF-1 by A, and HIF-1cells become resistant to A toxicity, one can learn more
about the toxicity pathway as well as the mechanisms is more highly expressed in AD transgenic mice. The
physiological consequences of enhanced glucose me-of amyloid resistance. To address the mechanisms in-
volved in resistance to A toxicity, a series of A-resis- tabolism in neurons are increased sensitivity to both
hypoglycemic stress and antipsychotic drugs that in-tant clones were derived from the rat sympathetic nerve-
like cell line PC12 and the central nervous system cell hibit glucose uptake.
line B12 by growth for 4 months in the presence of A-
and subsequent cloning (Behl et al., 1994; Sagara et al., Results
1996). Unlike the parental cells, these resistant clones
do not respond to high levels of A by dying or by Glycolytic Enzymes and Glucose Flux Are
accumulating peroxides. The resistant cells are also Upregulated in A-Resistant Cells
much less sensitive to H2O2 and t-butyl-H2O2, in part Since A-resistant nerve cells are resistant to multiple
due to the increased expression and activities of the forms of oxidative stress (Behl et al., 1994; Sagara et
antioxidant enzymes catalase and glutathione peroxi- al., 1996), it was asked if they alter their glucose metabo-
lizing pathways to produce a more reductive environ-
ment. Glycolysis, the sequential conversion of glucose*Correspondence: schubert@salk.edu
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Figure 1. Glycolysis Is Upregulated in A-Resistant Cells
(A) Hexokinase activity. Enzyme activity was measured in cell lysates and is expressed as percent control. Basal hexokinase activity for B12
was 91  6 nmol/min/mg and PC12 71  5.
(B) GAPDH activity and protein expression. GAPDH activity was measured in cell lysates and is expressed as percent control. Enzyme protein
and actin in the lysates were determined by Western blotting, and the ratio of enzyme protein to actin is presented in the right panel. The
parental line enzyme to actin ratio is set at 100%. There was no change in PC12 enzyme protein, but there was a significant increase in B12
enzyme protein in the two resistant lines. The basal GAPDH activity in PC12 was 135  9 and B12 172  11.
(C) Pyruvate kinase activity and enzyme protein. The data are presented as in (B). The parental enzyme activity for PC12 was 485  21 and
for B12 679.
(D) Cells were labeled with 3H-5-glucose for 3 hr, and the production of 3H2O determined and presented as percent control (100%). The basal
rates of 3H2O produced by the parental cells were 5.3  106 cpm/hr/106 cells for B12 and 4.1  105 cpm/hr/106 cells for PC12. All data are
the mean of at least three experiments plus or minus the standard error of the mean (SEM). Significantly different from control *p  0.01.
to pyruvate, is, in conjunction with the citric acid cycle, clones relative to their parental cells. The amount of
enzyme protein is also increased in the B12-resistantthe primary source of reduced NADH. To determine if
this pathway is upregulated in A-resistant cells, we cells. Finally, we observed a significant increase in py-
ruvate kinase activity in both of the B12-resistant cellanalyzed two sets of cells for the expression and activity
of several key glycolytic enzymes as well as for the rate lines but no change in this enzyme in the A-resistant
PC12 cells (Figure 1C). There is a decrease in PC12of glucose utilization. Three glycolytic enzymes were
studied in wild-type and two A-resistant clones of both pyruvate kinase protein, while there is an increase in
B12 pyruvate kinase protein. The observation that thePC12 and B12. Hexokinase, the irreversible first enzyme
in the glycolytic pathway, phosphorylates glucose to activities of all three enzymes are not increased in each
resistant cell line is consistent with the fact that individ-glucose-6-phosphate (G6P). Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) phosphorylates glycer- ual glycolytic enzymes may initially be in excess in some
cells (Esmann, 1978). While these data suggest that gly-aldehyde-3-phosphate and generates NADH, while py-
ruvate kinase, a major regulatory enzyme in the pathway, colysis may be upregulated in the A-resistant cells, the
critical factor is the rate of glucose metabolism. Wedephosphorylates phosphoenolpyruvate to generate
ATP and pyruvate. Pyruvate is, in turn, the entry point performed two assays to measure this parameter. The
first measures the breakdown of 3H-5 glucose to 3H2Ointo the citric acid cycle. Hexokinase activity is in-
creased in both of the A-resistant clones of PC12, but and the second the conversion of 14C-6-glucose to 14CO2.
Because neurons can use exogenous amino acids asin only one clone of the two resistant clones of B12
(Figure 1A). Figure 1B shows that the enzymatic activity an alternative energy source to glucose (Honegger et
al., 2002), all experiments were done in complete cultureof GAPDH is elevated in three of the four A-resistant
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Table 1. Hexose Monophosphate Shunt Activities
G6PDH 14CO2 from 14C-1-Glucose 14CO2 from 14C-6-Glucose HMS NADPH
(nmol/min/mg) (nmol CO2/hr/107 Cells) (nmol CO2/hr/107 Cells) (nmol CO2/hr/106 Cells) (pmol/mg)
PC12 46  5 8.4  0.4 3.3  0.5 5.1 105  11
PC12r1 87  7 (1.9) 33.8  0.9 (4.1) 9.6  1.6 (2.9) 24.2 (4.7) 240  31 (2.3)
PC12r7 73  6 (1.6) 17.0  1.2 (2.0) 12.3  2.3 (3.7) 4.7 222  17 (2.1)
B12 975  17 345  51 75  5 270 350  25
B12r2 901  40 422  30 135  13 (1.8) 287 406  44
B12r4 922  19 449  42 147  7 (1.9) 302 375  12
PC12 48  4 6.71  1.0 1.4  0.2 5.2 120  10
PC12  A 90  5 (1.8) 12.0  0.3 (1.8) 1.7  0.1 (1.2) 10.3 (2.0) 175  8 (1.5)
B12 835  51 295  27 47  3 248 450  35
B12  A 972  28 301  40 62  4 (1.3) 239 433  60
Primary nerve 20  1 17 4 1.5  0.3 15.5 330  55
Primary nerve  A 84  10 (4.2) 51  6 (3.0) 3.8  0.4 (2.5) 47.2 (3.0) 625  72 (1.9)
Primary glia 108  16 96  3 9.2  0.5 86.8 310  15
Primary glia  A 129  11 113  10 6.5  0.2 (0.71) 106.8 (1.2) 412  33 (1.3)
The activities of G6PDH, the molar amounts of NADPH, and glucose metabolism were measured as described in Experimental Procedures.
In some experiments, A1-42 was added at 2 M to cultures of PC12, B12, glia, and cortical neurons, and 4 days later glucose utilization,
NADPH, and enzyme activity were measured. The results are the means of six determinations  SEM. Values in parentheses are ratios which
are significantly different from controls (p  0.05).
medium containing 25 mM glucose. 3H-5 is released in The Hexose Monophosphate Shunt
Is Also Activatedwater during the conversion of 2-phosphoglycerate to
While the conversion of G6P to pyruvate producesphosphoenolpyruvate by enolase. Figure 1D shows that
NADH during glycolysis, the oxidation of G6P to CO2the rate of glucose metabolism as measured by this
and ribose-5-phosphate produces NADPH via the HMS.assay is significantly elevated in all of the A-resistant
Since NADPH is a cofactor required for the maintenancecells. Another assay for glucose metabolism through
of GSH and other antioxidant activities during conditionsthe glycolytic pathway to the citric acid cycle is the
of stress, we asked if the HMS is activated in themeasurement of 14C-6-glucose to 14CO2 produced at the
A-resistant cells and in AD brain. Two assays were-ketoglutarate dehydrogenase complex. Table 1 shows
used to examine this possibility. Glucose-6-phosphatethat the flux of 14C-6-glucose to 14CO2 is increased 2- to
dehydrogenase (G6PDH) is the first and rate-limiting3-fold in the four A-resistant cell lines. Therefore, both
enzyme in the shunt, and its activity is regulated bythe overall rate of glycolysis as well as the activity of
oxidative stress (Salvemini et al., 1999). Another assay,some of the major enzymes of the glycolytic pathway
which distinguishes HMS activity from glycolysis, is theare elevated in A-resistant cell lines.
measurement of 14CO2 production from 14C-1-glucose
and 14C-6-glucose. 14C-1-glucose releases 14CO2 both
from the citric acid cycle and via the shunt by the oxida-Glycolytic Enzymes Are Elevated in AD Brain
tive decarboxylation of 6-phosphogluconate to form ri-It is frequently assumed that when AD brain tissue is
bose-5-phosphate. 14C-6-phosphate releases 14CO2 fromexamined, one is measuring the physiological parame-
the citric acid cycle only. HMS activity is determined byters of dying cells. However, the reverse is a more likely
the subtraction of 14CO2 derived from 14C-6-glucose fromscenario, as the cells that are still biochemically active 14CO2 derived from 14C-1-glucose. Table 1 shows that(alive) are those that have survived the insults that
the HMS is more active in the PC12 A-resistant cell
caused the death of their neighbors. Surviving cells may
lines than in the parental cell line both in terms of G6PDH
constitute a resistant population which is analogous to activity and in the production of 14CO2. However, therecells selected in vitro for growth in the presence of toxic is no increased shunt activity in the A-resistant B12
concentrations of A, and it is very likely that they far cells relative to controls. This is probably because of
outnumber the cells which are in the process of dying. the very high basal level of HMS activity in the parental
Therefore, if the results with the A-resistant cell lines B12 cells. In both cell models, the HMS is more active
are related to the A response in AD brain, then it would than the glycolytic pathways. These changes are re-
be expected that glycolytic enzymes would also be ele- flected in an increase in the NADPH levels in the
vated in this tissue and in transgenic mice with AD pa- A-resistant PC12 cell lines as compared to the parental
thology. Figure 2 shows that this is indeed the case. line and a high initial amount of NADPH in the B12 paren-
GAPDH enzymatic activity is significantly elevated in tal cell line (Table 1). While it is not possible to measure
lysates from six individual AD brains relative to age- flux through the glucose degradation pathways in frozen
matched controls, as is the mean of the six Alzheimer’s autopsied AD brain tissue, the activity of G6PDH in tis-
GAPDH samples (993  225 nmol/min/mg) versus the sue lysates should reflect the HMS activity of the AD
mean of controls (570  75 nmol/min/mg) (Figure 2A, brain. Figure 2D shows that both G6PDH activity and
right panel). Pyruvate kinase activity and hexokinase enzyme levels are elevated in four of the six AD brain
activity (Figures 2B and 2C) are also elevated in most versus controls and when all AD brains are compared to
all controls (right panel). Therefore, as with the glycolyticof the AD cases relative to age-matched controls.
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Figure 2. Enzyme Activities in AD Brains
The ratio of enzyme to actin was determined for each sample and then the enzyme/actin ratio in the AD brain sample was divided by the
same ratio in the control brain. The lower right sections (A, B, and D) show this ratio; there were no significant differences between control
and AD brain in enzyme amount in (A and B), but there is a significant change in G6PDH. The mean increase in the enzymatic specific activity
relative to age-matched controls for all six AD cases is also shown. The mean enzyme specific activities for all six AD or all six controls are
as follows: GAPDH control, 570  75; GAPDH AD, 993  225; pyruvate kinase control, 729  70; pyruvate kinase AD, 1164  232; hexokinase
control 63  5.1; hexokinase AD 93  7.0. G6PDH control 12.45  2.1; and G6PDH AD 17.1  2.4. All experiments were repeated at least
three times with similar results. Significantly different from control, *p  0.05. “a” is AD brain and “c” is age-matched control brain.
pathway, the rate-limiting HMS enzyme is elevated in and astrocyte cultures were exposed to 2 M of A1-42,
and the activity of the HMS assayed 4 days later. A1-42AD brain as well as in clonal A-resistant neuronal cells.
To determine if the results observed with HMS and killed 10%–15% of the primary nerve cells, suggesting
that the surviving population is somewhat resistant. Ta-glycolytic enzymes in AD brain could be reproduced in
AD mice, we examined samples of the piriform cortex ble 1 shows that A1-42 activated the HMS in cortical
neurons to about the same extent as glycolysis. Theof very old (22 months) Tg2576 mice (Lim et al., 2001)
and age-matched controls. Like the AD samples, the amount of NADPH was also increased in the presence
of 2 M A1-42 (Table 1). When similar experiments weretransgenic mice have a large increase in G6PDH activity
(17.9  8.0 nmol/min/mg, n 	 6 versus 6.0  1.8 nmol/ done with the parental B12 and PC12 cell lines, A stimu-
lated the shunt activity in PC12 cells, but not significantlymin/mg, n 	 6, for controls, p  0.01). In addition, there
are slight increases in hexokinase and pyruvate kinase, in B12 cells, while glycolysis was weakly activated in
both. The increased glycolytic activity following A ex-but no change in GAPDH (Table 2). These results show
that the upregulation of major components of the glyco- posure was confirmed by the demonstration that the
activity of several of the glycolytic enzymes as well aslytic pathway occurs in AD brain and AD mice as well
as in A-resistant cell lines. the conversion of 3H-5-glucose to 3H2O through the gly-
colytic pathway is activated in cells exposed to A for
4 days (Table 2; Figure 5K).A Exposure Directly Enhances HMS Activity
and Glucose Uptake Although nerve cells have been the primary focus in
AD, glia are the majority cell type in the brain. We there-Because oxidative stress can enhance the flux of glu-
cose through the HMS by as much as 100-fold (Salvemini fore asked if exposure to A had any effect on glucose
metabolism in glia. Tables 1 and 2 show that primaryet al., 1999), it is possible that the short-term exposure
of cells to the prooxidant Awill also enhance this path- rat cortical astrocytes exposed to A identically to the
cortical neurons have a small but significant increase inway. To examine this possibility, the parental B12 and
PC12 cell lines as well as primary rat cortical neurons HMS activities, but that there is a decrease in glycolysis
Amyloid, HIF-1, and Glucose Metabolism
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Table 2. Glycolysis and Glucose Uptake
3H2O from 5-3H-Glucose Hexokinase Pyruvate kinase GADPH 14C-Deoxy-Glucose Uptake
(pm/hr/106 Cells) (nmol/min/mg) (nmol/min/mg) (nmol/min/mg) (nmol/min/106 Cells)
B12 3.2  106 111  10 432  31 151  8 33  1.5
B12  A 5.1  106 (1.6) 146  8 (1.3) 693  50 (1.6) 181  10 41  2.8 (1.3)
PC12 5.8  105 59  7 420  11 113  5 4.8  0.7
PC12  A 9.5  105 (1.6) 82  10 688  51 (1.6) 117  12 9.7  0.5 (2.0)
Nerve 1.2  105 175  11 460  22 1020  74 3.6  0.8
Nerve  A 2.1  105 (1.7) 284  18 (1.6) 736  47 (1.6) 1225 85 (1.2) 7.1  1.3 (2.0)
Glia 4.5  105 537  22 1780  186 2470  51 7.8  1.2
Glia  A 3.2  105 (0.71) 595  17 2571  93 2280  175 4.3  1.2 (0.6)
Control mice – 40  6 892  65 398  42 –
Tg2576 mice – 52  4 (1.3) 1128  41 (1.3) 337  23 –
B12  MIM 6.7  106 (2.1) 133  5 (1.2) 820  55 (1.9) 211  30 (1.4) 66  3 (2.0)
PC12  MIM 11.0  105 (1.9) 100  6 (1.7) 630  32 (1.5) 180  21 (1.6) 6.3  0.5 (1.3)
Nerve  MIM 1.7  105 (1.4) 225  31 (1.4) 787  80 (1.7) 1140  110 6.5  0.4 (1.8)
B12Z 4.6  106 132  10 520  31 138  12 29  4
B12 ZH4 8.3  106 (1.8) 211  38 (1.6) 780  70 (1.5) 207  5 (1.5) 46  3 (1.6)
B12 ZH8 7.8  106 (1.7) 290  20 (2.2) 884  27 (1.7) 166  15 (1.2) 38  6 (1.3)
The conversion of [53H]glucose to 3H2O, the uptake of 14C-deoxyglucose, and the determination of enzymatic activities were done as described
in Experimental Procedures. 2 M A1-42 was added to cultures 4 days before assaying the above activities. Either 100 M (B12 and PC12)
or 50 M (primary nerve) MIM were added 24 hr before the assays. The uptake of 14C-deoxyglucose was done in 1.6 mM deoxyglucose. The
results with the cell lines are the mean of three determinations  SEM. The data of the AD (Tg) mice represent 4 enzyme assays from each
of 6 individual animals in each group (24 assays total for each enzyme). Increases or decreases in parentheses are significant (p  0.05).
(Table 2). The glial cells are, however, initially several parental and A-resistant B12 and PC12 cells were ex-
posed to normal growth medium containing decreasedfold more active in terms of overall glucose metabolism
than their neuronal counterparts. An additional parame- amounts of glucose, and cell viability was measured 2
days later. Figures 4A and 4B show that the A-resistantter relevant to glucose metabolism is the relative rate
of glucose uptake. When the rate of 3H-deoxyglucose cells die more readily at higher concentrations of glu-
cose than their parental cell lines. In support of theuptake is examined, there are significant increases in
B12 and PC12 A-resistant clones (Figures 3A and 3B) argument that higher metabolic rates lead to greater
sensitivity to glucose starvation, B12 cells, which haveand in cortical neurons exposed to amyloid (Table 2).
In contrast, there is a decrease in glial cell deoxyglucose a higher metabolic rate than PC12 (Tables 1 and 2), die
at a 2-fold higher concentration of glucose than PC12uptake following a 4 day exposure to 2 M A1-42 (Table
2). What are the biological consequences of this cells. To rule out the possibility that A resistance leads
to an overall increased sensitivity to toxic insults, cellsA-induced change in nerve glucose metabolism?
were treated with increasing concentrations of thapsi-
gargin, a potent inducer of the endoplasmic reticulumA Resistance Leads to Increased Sensitivity
(ER) stress response (Wong et al., 1993). Figure 4Cto Glucose Starvation
shows that A-resistant cells were, in contrast to glu-The nervous system has an extremely high rate of energy
cose starvation, more resistant to thapsigargin than theconsumption and glucose is its primary source of en-
parental lines. To determine if A-enhanced glucoseergy. It follows that any additional increase in energy
sensitivity could be reproduced in cortical neurons, weburden could lead to a concomitant increase in sensitiv-
ity to lower glucose levels. To examine this possibility, exposed primary cultures of rat cortical neurons for 4
Figure 3. Glucose Uptake in A-Resistant
Cell Lines
The uptake of 14C-U-deoxyglucose into B12
(A), PC12 (B), and their resistant clones was
assayed in the absence of A. The concentra-
tion of exogenous deoxyglucose was 1.6 mM.
The experiments were repeated at least three
times with similar results.
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Figure 4. Glucose Starvation of A-Resistant Cells
Exponentially dividing cells of PC12 (A) or B12 (B) were plated in normal growth medium in 96-well plates at 5  103 cells per well in the
absence of A. Twenty hours later the medium was replaced with a serial dilution of normal (25 mM) glucose containing medium into glucose-
free medium, and viability determined 3 days later (C). B12 and its two A-resistant clones were exposed to increasing concentrations of the
ER stress inducer thapsigargin and cell viability measured 48 hr later. In a similar experiment to (A), cells were grown in complete medium in
the presence of increasing concentrations of deoxyglucose (D and E). Three days later cell viability was determined by the calcein AM assay.
The data are presented as the means of triplicate determinations  SEM. The experiment was repeated at least three times. Using a Wilcoxon
signed ranks test for two related samples, p  0.01 for the resistant versus parental cells in all cases.
days to a concentration of A1-42, which kills about 10% A exposure produces a phenotype in which cells die
more readily in higher minimal concentrations of exoge-of the nerve population. Under these conditions, there
is an upregulation of the HMS and glycolysis (Tables 1 nous glucose than cells not exposed to amyloid.
and 2). The surviving neurons were examined for their
sensitivity to glucose starvation. After 4 or 8 days in A-Resistant Cells Are Also More Sensitive
to Antipsychotic Drugs2 M A1-42, the treated cells were significantly more
sensitive to glucose starvation than the untreated cells Glucose is transported into cells by a family of sodium-
independent transporters, and in neurons most of the trans-(Figures 5A–5C, 5E, 5F, and 5J, quantitated in 5L). There
was no change in cell viability when a similar experiment port is through GLUT3 (Maher et al., 1991). It has been
shown that some antipsychotic drugs inhibit GLUT3-was done with astrocytes.
Deoxyglucose is taken up by cells via the glucose dependent glucose uptake in nerve cells (Ardizzone et
al., 2001). These data may explain earlier observationstransport system, phosphorylated by hexokinase, but
cannot be further metabolized, thereby effectively shut- that antipsychotic drugs can cause hyperglycemia and
diabetes in psychiatric patients (Thonnard-Neumann,ting down glycolysis and the HMS. If a higher rate of
glycolysis is responsible for cell death following glucose 1968). Since A resistance makes nerve cells more sen-
sitive to glucose starvation, it would be predicted thatdeprivation, then it would be predicted that the exposure
of cells to increasing concentrations of deoxyglucose the resistant cell lines would also be more sensitive to
these antipsychotic drugs. Figure 5M shows that this iswould kill A-resistant cells more readily than the paren-
tal group. Figures 4D and 4E show that when B12 and indeed the case, for a concentration of clozapine or
fluphenazine that kills only 20% of the parental PC12PC12 cells are grown in normal culture medium and
exposed to 0.1–100 mM deoxyglucose, the resistant cells kills over 70% of the A-resistant PC12 cells. Flu-
phenazine was also more toxic to B12 A-resistant cellscells are more sensitive to deoxyglucose than the paren-
tal cell lines. Similar results were obtained with primary than the parental cells, while the major metabolite of
clozapine, clozapine-N-oxide, which is inactive incortical neurons; the data for 50 M deoxyglucose are
shown in Figures 5D and 5I. These results reveal that blocking glucose uptake, is nontoxic. When we repeated
Amyloid, HIF-1, and Glucose Metabolism
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Figure 5. Neurons Exposed to A Are More Sensitive to Glucose Starvation and Antipsychotic Drugs
Cortical neurons were exposed to 2 M A1-42 for 4 or 8 days where indicated. Cells were then placed in fresh medium containing the indicated
amounts of glucose, deoxyglucose, or drugs, and 2 days later cell viability was assayed by calcein AM viability stain. The conversion of [5-3H]glu-
cose to 3H2O was also monitored (K). (A) Control. (B) A1-42. (C) 5% normal glucose (1.25 mm). (D) 50 M deoxyglucose. (E) 8 days, 5% glucose,
note cells more clumped. (F) 5% glucose plus A. (G) Control plus 20 M clozapine. (H) A1-42 plus clozapine. (I) 50 M deoxyglucose plus
A. (J) Eight days, 5% glucose plus A. The data are quantified in (L) as the mean of four determinations  SEM. Statistically different from
control, *p  0.01. (M) Increasing amounts of clozapine, fluphenazine, and clozapine N-oxide (0–100 M) were added to cultures of PC12,
B12, and their A-resistant derivatives. Two days later cell viability was determined by the calcein AM assay. The data for 20 M drug are
shown. The data are the means of triplicate determinations  SEM. Significant difference from control, *p  0.01.
these experiments with primary cortical neurons ex- and the stable expression of a nondegradable form of
posed to marginally toxic concentrations of A, similar HIF-1 reproduce the physiological consequences of
results were obtained. Figures 5G, 5H, and 5L show that A resistance and lower ROS accumulation in cells. Al-
while 2 M A1-42 or 20 M clozapine were relatively though the highly protease sensitive HIF-1 protein is
nontoxic alone, when combined, the majority of the cells degraded in our post-mortem AD brain samples, an ele-
in the cortical population died. These results show that vated expression of HIF-1 was observed in AD trans-
there can be a toxic interaction between some antipsy- genic mice.
chotic drugs and A-resistant cells. Given the profound Two assays were used to measure HIF-1 activation,
effects of A on glucose metabolism and cell physiol- electrophoretic mobility shift assays (EMSAs), and the
ogy, what is the mechanism by which A mediates this appearance of HIF-1 protein by Western blotting. Fig-
effect? ure 6A shows that both HIF-1 binding to DNA and HIF-
1 protein are increased in the A-resistant clones of
PC12 and B12 relative to the parental clones. There isA Induces HIF-1
a higher basal expression of HIF-1 activity in wild-typeThe above data show that glucose metabolism is upreg-
B12 cells, perhaps reflected in their high basal glucoseulated by A. Earlier studies showed that metal chelators
metabolism (Table 2). When PC12, B12, and primaryprotect cells from A toxicity (Schubert and Chevion,
cultures of rat cortical neurons are exposed to concen-1995). Since iron chelators activate the transcription fac-
trations of A sufficient to enhance glycolysis, there istor HIF-1, which, in turn, increases the transcription of
an induction of HIF-1 activity as measured in an EMSAgenes for the glycolytic pathway and glucose uptake,
time course (Figure 6B), and an increase in HIF-1 pro-it was asked if HIF-1 is responsible for the changes
tein (Figure 6C). We were unable to detect HIF-1 DNAassociated with A resistance. This issue was ad-
binding in the cortical neuron cultures, presumably be-dressed in five ways. It is shown that HIF-1 protein
cause cortical neurons make different isoforms of HIF-is stabilized in A-resistant cell lines, that A directly
induces HIF-1 DNA binding, and that metal chelators 1 which poorly recognize the response element in the
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Figure 6. HIF-1 Activity and A
(A) PC12 wild-type and A-resistant clones r1 and r7, and B12 wild-type and A-resistant clones r2 and r4 were assayed for HIF-1 activity
by EMSA and Western blotting.
(B) Cells were exposed to 10 M A and EMSAs done at the indicated times.
(C) Left panel: Western blots of HIF-1 following exposure of PC12 and B12 to 10 M A (10) or solvent (0). Actin was a loading control. Right
panel: Western blot of primary cortical neurons with anti-HIF-1 6 hr following exposure to the indicated concentration of A1-42.
(D) Cortical extracts from six 22- and 23-month-old Tg2576 mice and six age-matched controls were run on SDS acrylamide gels and blotted
with anti-HIF-1 or anti-actin. 
, control; , Tg2576.
(E) Cells were exposed to 100 M MIM and EMSAs done at the indicated times.
(F) Cortical neurons were exposed to 50 M MIM and lysates immunoblotted with anti HIF-1 or actin at the indicated times.
(G and H) PC12 or B12 cells were exposed to the indicated concentration of A and/or MIM and the ability to reduce MTT assayed 20 hr
later.
(I) First four bars from left: cortical neurons were exposed to the indicated concentrations of MIM or A1-42 and cell viability assayed by calcein
AM 2 days later. Last three bars on right: cortical cells were either exposed to 2 M A for 4 days and then exposed to 20 M A1-42 for 2
days (20 M A  A pre) or no additional A (2 M A pre). Some cells were exposed at 4 days directly to 20 M A without preexposure
(20 M A). Significantly different from controls, *p  0.01.
EPO enhancer (Drutel et al., 2000). There is, however, a HIF-1 Activation Is Sufficient for Neuroprotection
To determine if the induction of HIF-1 activity is sufficientclear accumulation of HIF-1 in the cortical cells follow-
ing A exposure that is detectable at 2 M A1-42 (Figure to cause resistance to A, HIF-1 activity was induced
by the metal chelator mimosine (MIM) or by the expres-6C). To determine if the cell culture results could be
reproduced in vivo, 22-month-old AD transgenic mouse sion of a nondegradable form of HIF-1. It was then
asked if cells are protected from A toxicity. When PC12cortex was compared to age-matched controls. Figure
6D shows that five of the six AD mice had elevated HIF- and B12 cells were exposed to MIM, both show an
increase in HIF-1 DNA binding (Figure 6E). Figures 6G1 expression compared to control animals.
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Figure 7. Constitutive HIF-1 Expression
B12 cells were transfected with a nondegradable form of HIF-1 and assayed for several phenotypic changes.
(A) B12 cells permanently transfected with empty vector (B12Z, insert), and two mutant HIF-1 transfected clones (B12H3 and B12H8, insert)
were exposed to A1-42 and their reactions to the peptide monitored by the MTT assay 24 hr later. G6PDH was also assayed by Western
blotting in these three cell lines (insert). Closed diamonds, B12Z (empty vector); closed triangles, B12ZH3 (mutant HIF-1); closed squares,
B12H8 (mutant HIF-1).
(B) B12 and B12 A-resistant cells, B12 cells exposed to 100 M or 2 M A1-42 for 20 hr, or the mutant HIF-1 transfected cells were assayed
for intracellular peroxides (ROS). The ROS data are presented as fraction of control (B12 or B12Z) values.
(C) Either the enzymatic activity of G6PDH (left side) or total activity of the shunt (HMS, right side) were assayed for B12Z(1), B12ZH3(2), and
B12ZH8(3).
(D) B12Z (closed circles), B12ZH3 (Xs) or B12ZH8 (open triangles) were plated in decreasing amounts of glucose and cell viability determined
3 days later by the calcein assay. Significantly different from control, *p  0.01.
and 6H show that MIM also protects both PC12 and toxicity. The expression of the nondegradable form of
HIF-1 also increases glycolysis (Table 2).B12 cells from A to toxicity. To determine if primary
cultures of rat cortical neurons respond in a similar man-
ner, cultures were exposed to MIM, followed by a toxic A Resistance Leads to Reduced ROS
There is frequently a reciprocal relationship betweenconcentration of A. MIM increases HIF-1 levels and
protects cortical neurons from A toxicity (Figures 6F glycolysis and respiration through the mitochondrial
electron transport chain (Webster et al., 1990), and en-and 6I). Table 2 shows that MIM enhances glycolysis
and glucose uptake in all three sets of cells. Finally, hanced glycolysis caused by HIF-1 activation can lead
to the reduction of ROS accumulation (Michiels et al.,when primary cortical neurons were exposed to a sub-
toxic dose of A1-42 followed 4 days later by a toxic dose, 2002). Figure 7B shows that in B12 cells resistant to A,
or cells exposed to nontoxic levels of A, there is athe cells were protected from A to a level similar to
MIM protection (Figure 6I). decrease in intracellular ROS. A similar reduction in ROS
is observed in cells in which HIF-1 is activated by MIMTo ask if the activation of HIF-1 alone can render cells
resistant to A, a nondegradable mutant of HIF-1 was or by the overexpression of the nondegradable form of
HIF-1 (Figure 7B).made (Srinivas et al., 1999). Clones transfected with the
mutated HIF-1 have elevated levels of HIF-1 protein The HMS is more active in A-resistant cells and in
cells exposed to low levels of A (Table 1). To determinecompared to a clone transfected with the empty vector
(Figure 7A, insert). When tested for the ability to resist if HIF-1 is sufficient to induce this pathway, HIF-1 was
activated by the expression of the nondegradable HIF-A toxicity, the mutant HIF-1 expressing cell lines dem-
onstrated a higher tolerance to A (Figure 7A). This result 1 and the activity of the shunt monitored. Figure 7C
shows that constitutive HIF-1 activated G6PDH en-shows that HIF-1 alone is able to rescue cells from A
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zyme activity and HMS activity as determined by moni- (3) The expression of a nondegradable mutant of HIF-
1 also protects cells from A (Figure 7A). (4) Exposuretoring radioactive glucose metabolism. The expression
of cells to low levels of A induces HIF-1 and protectsof G6PDH protein is also increased (Figure 7A, insert).
nerve cells from the toxicity of high A concentrationsTherefore, along with glycolysis, HIF-1 activation pro-
(Figure 6). (5) The direct activation of HIF-1 by MIM or amotes HMS activity, generating the potent reducing mol-
nondegradable form of HIF-1mimics the physiologicalecule NADPH.
consequences of nontoxic levels of A (Figure 7; Table
2). (6) HIF-1 is more highly expressed in AD transgenicThe Activation of HIF-1 Enhances Sensitivity
mice than in age-matched controls (Figure 6D).to Glucose Starvation
Iron chelators protect cultured cells from A (SchubertSince cells overexpressing HIF-1 have an enhanced
and Chevion, 1995) and inhibit the progression of ADrate of glycolysis (Table 2), it follows that they should
(McLachlan et al., 1991). Furthermore, treating AD trans-be more sensitive to glucose starvation than cells trans-
genic mice with a metal chelator clioquinol reversesfected with plasmid alone. To test this possibility, cells
some aspects of AD-like pathology (Cherny et al., 2001)were plated in normal medium, and the next day the
and blocks MPTP-induced Parkinson’s pathology (Kaurmedium was replaced with complete medium containing
et al., 2003). Clioquinol induces HIF-1 with an IC50 of 600decreasing amounts of glucose. Cell viability was deter-
nM (data not shown). Although the published resultsmined 3 days later. Figure 7D shows that clones of cells
were attributed to metal chelators binding to prooxidantexpressing the nondegradable HIF-1 were killed more
metal ions, our data strongly suggest that an importantreadily than cells containing the plasmid alone. These
part of their success is due to their ability to inducedata show that while HIF-1 expression is protective for
HIF-1. In contrast to nerve cells, glycolysis is downregu-A toxicity, its activity also leads to increased sensitivity
lated by A in glial cells (HMS activity is, however, upreg-to glucose starvation.
ulated), even though HIF-1 is activated by A in these
cells (data not shown).Discussion
The activation of HIF-1 has been associated with both
death and antideath pathways (Piret et al., 2002). How-One manifestation of AD is the oxidative damage of
ever, in most cases ROS and prooxidants like arseniteproteins, lipids, and nucleic acids in the brain (Smith et
stabilize HIF-1 and induce HIF-1 DNA binding (Duyn-al., 1997). To combat this type of stress, cells need
dam et al., 2001), and hypoxic preconditioning producesto produce large amounts of reducing equivalents to
tolerance to hypoxic-ischemic brain injury (Bernaudinregenerate GSH and to support the function of antioxi-
et al., 2002). Since HIF-1 activation protects nerve cellsdant enzymes. There are two major ways of producing
from both oxidative stress and A toxicity, it is likelythese molecules. One is through glycolysis, which pro-
that the upregulation of this transcription factor is aduces NADH, and the other is the HMS that generates
general neuroprotective mechanism against oxidativeNADPH. The above data show that the flux of glucose
insults. Indeed, the A-resistant cell lines used in thisthrough both pathways is elevated in amyloid-resistant
study are resistant to glutamate, cystine starvation,
neuronal cell lines and primary cortical nerve cells ex-
H2O2, arsenite, and rotenone (Dargusch and Schubert,posed to sublethal concentrations of A1-42. The cells in 2002), as well as thapsigargin (Figure 4C). HIF-1 activa-
AD brain, which by definition represent the surviving,
tion enhances the rate of glycolysis, as well as the activ-
more A-resistant population, also increase the net ac- ity of the HMS shunt (Figure 7). Therefore, it is likely that
tivity of enzymes in both pathways. These results are the neuroprotection mechanism is through the en-
consistent with those showing an increased level of hanced production of NADH and NADPH from glycolysis
G6PDH in surviving pyramidal neurons (Russell et al., and the HMS, and an increase in the synthesis of the
1999) and an increase in two enzyme activities associ- antioxidant pyruvate via glycolysis. All three molecules
ated with the HMS in AD brain (Palmer, 1999). The ability would contribute to a reduction in intracellular ROS and
of A to increase glycolysis, HMS activity, and antioxi- produce a more reductive environment to ward off future
dant defenses may explain the observation that low lev- toxic insults. Stress resistance is relative, and the more
els of A are neuroprotective against the prooxidant resistant state can obviously be overridden by higher
conditions of tissue culture, while higher concentrations concentrations of a prooxidant or more stressful physio-
are toxic (Yankner et al., 1990). These changes in AD logical conditions (Dargusch and Schubert, 2002). Since
brain may be a reflection of metabolic changes within A plaque density is not highly correlated with nerve
the individual cells or they may be due to anatomical cell loss or cognitive decline (Terry, 2000), it is possible
changes, such as altered nerve/glia ratios, due to the that at least an early function of A in aging is neuropro-
progression of the disease. In cultured cells, and possi- tection.
bly in AD, the increase in metabolic activity is a conse- The increased rate of glucose consumption does,
quence of the activation of HIF-1 by subtoxic amounts however, have some negative physiological conse-
of A. The conclusion that HIF-1 regulates the A re- quences in clinical situations where glucose uptake is
sponse is based upon the following observations: (1) limiting. These include patients exposed to certain
A-resistant cell lines have elevated HIF-1 expression classes of antipsychotic drugs, type II diabetes, and
and activity. (2) An iron chelator that stabilizes HIF-1 ischemia. Phenothiazine-based antipsychotic drugs
and increases HIF-1 binding to DNA induces expression such as chlorpromazine induce hyperglycemia and dia-
of the same group of enzymatic activities as low concen- betes in some patients (Hiles, 1956). It has more recently
trations of A, and protects cell lines and primary corti- been established that a large number of antipsychotic
drugs effectively inhibit glucose uptake via competitioncal neurons from A toxicity (Figures 6 and 7; Table 2).
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for glucose transporters (Dwyer et al., 1999). Since these enzymatic activities are enhanced in AD brain and in
drugs also cause an increased sensitivity to glucose A-resistant cells reconciled with the observations that
starvation in A-resistant clonal nerve cells and cortical glucose metabolism is reduced in PET scans? As men-
nerve cells exposed to low levels of A1-42 (Figure 5), it tioned above, all of the biopsy studies on energy metab-
follows that the administration of this subset of antipsy- olism were done with relatively young AD patients hav-
chotics to preclinical or mild AD patients could lead ing an average age of less than 60 years (Bowen et al.,
to the expedited death of cells with increased glucose 1979; Sims et al., 1981, 1983, 1987). In addition, an initial
dependency due to A exposure. gain and then loss of G6PDH activity with age in AD
Diabetes mellitus (DM) is a probable risk factor for patients has also been noted (Palmer, 1999). It is there-
AD, doubling the likelihood of developing the disease fore possible that the results on cultured cells reported
(Ott et al., 1999). Insulin stimulates glucose uptake, and here reflect an early response of neurons to amyloid
AD patients with reduced insulin levels have significantly that is eventually overridden in older individuals by the
lower cognitive skills than individuals with normal insulin cumulative effects of age and toxicity, resulting in a net
levels (Craft et al., 1996). Although only a small percent- decline in nerve glucose metabolism. However, some
age of the glucose supply to neurons is delivered by aspects of the A-resistant phenotype must persist in
an insulin-dependent mechanism (Schulingkamp et al., older individuals since G6PDH and glycolytic enzymes
2000), a loss of the insulin-dependent glucose uptake are clearly upregulated in our AD patients, whose aver-
may be sufficient to cause the death of A-resistant cells age age was 86. The net decrease in fluorodeoxyglucose
with a high metabolic rate. In fact, the administration of uptake observed by PET could also be a result of
glucose and insulin together enhances the memory of changes in vascular blood flow due to A damage (Hor-
AD patients, while giving glucose alone does not have wood and Davies, 1994) and the additive effects of nerve
this effect (Craft et al., 1996; Manning et al., 1993). There- cell death, nerve terminal destruction, and A-induced
fore, a lack of insulin-stimulated glucose uptake in the reduction of glial cell glucose uptake (Table 2) (Parpura-
population of A-resistant nerve cells with a high glu- Gill et al., 1997).
cose requirement could lead to a more rapid progression The global changes in glucose metabolism outlined
of the disease. above are examples of system-wide energy dynamics
The role of glucose metabolism in AD is controversial, which may play key roles in both AD and other neurode-
but the current dogma is that the use of glucose by generative diseases (Strohman, 2002). The A-induced
nerve cells in the affected brain areas is impaired (Blass, changes in glucose metabolism that cause reduced ROS
2001; Gibson, 2002). This conclusion is based primarily levels in cells are analogous to the changes in energy
upon the use of 2-18fluoro-2 deoxyglucose and PET to metabolism that have recently been associated with ex-
measure in situ glucose uptake (Mielke et al., 1991), and tended life span in yeast (Lin et al., 2002) and fungi
the apparent inactivation in post-mortem samples of a (Dufour et al., 2000), and are likely to reflect a life exten-
few enzymes involved in energy metabolism (Blass, sion program in response to oxidative stress at the cellu-
2001). In contrast to the data suggesting a decrease in lar level. However, the biological consequences of a
glucose metabolism in AD, several earlier studies dem- neuroprotective increase in nerve cell glucose utilization
onstrated that in viable biopsied AD brain tissue there is may be an increased risk of nerve cell death associated
a highly significant increase in the rate of CO2 production with diabetes, ischemia, and psychoactive drug use.
from glucose and an increase in O2 uptake in AD versus
control brain tissue (Bowen et al., 1979; Sims et al., 1981, Experimental Procedures
1983). Other studies examining O2 uptake in biopsied AD
tissue showed that the rate of O2 consumption in the Cell Culture
The B12 and PC12 clonal cell lines, their A-resistant derivatives,presence of a mitochondrial uncoupling agent is the
and their culture have been described (Behl et al., 1994; Sagara etsame in AD versus control tissue, but under conditions
al., 1996). Mouse and rat astrocytes were prepared from newbornof submaximal activity, which reflect the in vivo situation,
animals as described (Parpura-Gill et al., 1997). Primary cortical
AD samples have nearly 2-fold higher rates of O2 uptake neurons were prepared from day 17 rat embryos (Li et al., 1997).
(Sims et al., 1987). It should be noted that the mean age Cell viability was measured by three assays. Following the experi-
for the biopsied patients in the above studies was less mental protocol, viable cells were assayed by incubation with the
fluorescent viable stain calcein AM which is concentrated in livingthan 60 yrs. Supporting the enzyme activity measure-
cells (Live Dead Assay; Molecular Probes, Eugene, OR) and the cellsments of G6PDH are immunohistochemical data which
scored manually from 35 mM culture dishes. At least ten randomshow an increase in enzyme amount in surviving neurons
fields were scored for each data point. When A was not used, thewithin AD brain (Russell et al., 1999). Finally is the obser-
MTT assay was sometimes used in addition to calcein AM. The MTT
vation that cerebral metabolism in young Down’s syn- assay reflects the toxicity of A, but not necessarily cell lysis by A
drome patients is elevated relative to controls, while it (Liu et al., 1997). Flow cytometry and Western blotting were done
is slightly lower in older patients (Schwartz et al., 1983). as described (Tan et al., 2001).
Down’s syndrome patients always develop the patho-
logical features of AD (Wisniewski et al., 1985). The latter AD Brain
All autopsied brain samples were obtained from Drs. Carol Millerdata are all consistent with enhanced glucose metabo-
and Jenny Tang at the Alzheimer’s Disease Research Center (ADRC)lism in AD versus control tissue, at least in the early
in the University of Southern California School of Medicine, Losstages of the disease, and agree with our data on both
Angeles, CA. All material was from the same area of the frontal
the A-resistant cell lines, transgenic mice, and primary cortex and quick frozen after removal. All AD cases and controls
cortical neuron cultures exposed to marginally toxic lev- were matched pairwise for age, sex, and in most cases, post-mor-
els of A. tem time (PMT). The CERAD criterion for plaque density in the AD
samples had a mean of 3.5  1, a low toward moderate value. InHow are the data showing that glucose flux and HMS
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Figure 3, the following were shown: (C1) normal control brain, fe- antipsychotic drugs risperidone and clozapine, and structural ana-
logs of clozapine. Brain Res. 923, 82–90.male, age 94, post-mortem time 4.5 hr; (A1) AD brain, female, age
95, PMT 4.5 hr; (C2) control brain, female, age 87, PMT 6 hr; (A2) Arneson, G.A. (1964). Phenothiazine derivatives and glucose metab-
AD brain, female, age 86, PMT 6 hr; (C3) control brain, male, age olism. J. Neuropsychiatry 5, 181–185.
88, PMT 2 hr; (A3) AD brain, male, age 85, PMT 4.5 hr; (C4) control
Ashcroft, S.J.H., Weerasinghe, L.C.C., Bassett, J.M., and Randle,
brain, male, age 69, PMT 8 hr; (A4) AD brain, male, age 75, PMT 2
P.J. (1972). The pentose cycle and insulin release in mouse pancre-
hr; (C5) control brain, female, age 91, PMT not available; (A5) AD
atic islets. Biochem. J. 126, 525–532.
brain, female, age 90, PMT 4.5 hr; (C6) control brain, female, age
Behl, C., and Schubert, D. (1993). Heat shock partially protects rat86, PMT 4 hr; and (A6) AD brain, male, age 86, PMT 4.5 hr. Brain
pheochromocytoma PC12 cells from amyloid  peptide toxicity.tissue from AD transgenic mice were obtained from Dr. Giselle Lim
Neurosci. Lett. 154, 1–4.at the University of California, Los Angeles (Lim et al., 2001). 22- or
23-month-old Tg2576 mice and age-matched controls were per- Behl, C., Davis, J.B., Lesley, R., and Schubert, D. (1994). Hydrogen
fused with saline with a protease inhibitor cocktail, and the brain peroxide mediates amyloid beta protein toxicity. Cell 77, 817–827.
regions were snap frozen in liquid nitrogen and stored at 
80C. Bernaudin, M., Tang, Y., Reilly, M., Petit, E., and Sharp, F.R. (2002).
The piriform cortex that had visible AD pathology was examined. Brain genomic response following hypoxia and re-oxygenation in
the neonatal rat. J. Biol. Chem. 277, 39728–39738.
Enzyme Assays Blass, J.P. (2001). Brain metabolism and brain disease: is metabolic
Three assays were used for glucose utilization. The first was the deficiency the proximate cause of Alzheimer dementia? J. Neurosci.
formation of 3H2O from [5-3H]glucose performed as previously de- Res. 66, 851–856.
scribed (Ashcroft et al., 1972). The last two assays involved the
Bowen, D.M., White, P., Spillane, J.A., Goodhardt, M.J., Curzon, G.,production of 14CO2 from 14C-glucose. D-[1-14C]glucose and D-[6- Iwangoff, P., Meier-Ruge, W., and Davison, A.N. (1979). Accelerated14C]glucose (NEN, Boston, MA) were used to measure net glucose
ageing or selective neuronal loss as an important cause of dementia.utilization via the HMS and the citric acid cycle pathways, respec-
Lancet i, 11–14.tively, according to published procedures (Hyslop et al., 1988). To
Brand, K. (1997). Aerobic glycolysis by proliferating cells. J. Bioen-examine glucose uptake, cells were washed twice with glucose-
erg. Biomembr. 29, 355–364.free DMEM and incubated in this medium for 1 hr at 37C.
[U-14C]deoxyglucose was then added at 0.5Ci/ml to a final concen- Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D.,
tration of 1.6 mM and uptake monitored over 20 min during which McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., et al.
the time uptake was linear. Uptake was stopped by washing the (2001). Treatment with a copper-zinc chelator markedly and rapidly
cells three times with ice-cold phosphate-buffered saline and dis- inhibits beta-amyloid accumulation in Alzheimer’s disease trans-
solving the cells in 0.2 N NaOH for isotopic counting. Uptake was genic mice. Neuron 30, 641–642.
completely inhibited by 10 mM phloretin, establishing the specificity Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., She-
of uptake through a glucose transporter. All enzymes were assayed line, Y., Luby, J., Dagogo-Jack, A., and Alderson, A. (1996). Memory
by the standard optical methods (Worthington, 1947). Frozen brain improvement following induced hyperinsulinemia in Alzheimer’s dis-
tissue was homogenized in assay buffers and stored at 
80C; cell ease. Neurobiol. Aging 17, 123–130.
cultures were washed two times with phosphate-buffered saline
Dargusch, R., and Schubert, D. (2002). Specificity of resistance toand lysed in the same buffer by sonication. In all cases, care was
oxidative stress. J. Neurochem. 81, 1394–1400.taken to ensure that the reactions were linear and substrate depen-
Drutel, G., Kathmann, M., Heron, A., Gros, C., Mace, S., Schwartz,dent. NADPH was measured as described (Zhang et al., 2000).
H.C., and Arrang, J.M. (2000). Two splice variants of the hypoxia-
inducible factor HIF-1 as potential dimerization partners of ARNT2EMSAs
in neurons. Eur. J. Neurosci. 12, 3701–3708.Nuclear extracts were prepared and used for an EMSA specific for
Dufour, E., Boulay, J., Rincheval, V., and Sainsard-Chanet, A. (2000).HIF-1. A 32P-labeled 24 bp oligonucleotide (5-GCCCTACGTGCTGC
A causal link between respiration and senescence in PodosporaCTCGCATGGC-3) from the mouse EPO 3 enhancer was used as
anserina. Proc. Natl. Acad. Sci. USA 97, 4138–4143.probe (Maxwell et al., 1999). The identity of the retarded bands was
confirmed by adding antibodies specific for HIF-1 or HIF-1 to the Duyndam, M.C., Hulscher, T.M., Fontijn, D., Pinedo, H.M., and Bo-
incubation mixture (Santa Cruz Biotechnology, Santa Cruz, CA). A ven, E. (2001). Induction of vascular endothelial growth factor ex-
super shift of the retarded bands was observed (data not shown). pression and hypoxia-inducible factor 1alpha protein by the oxida-
In addition, cell extracts were incubated with a 100-fold excess of tive stressor arsenite. J. Biol. Chem. 276, 48066–48076.
unlabeled wild-type oligo or with an oligo mutated in the HRE region; Dwyer, D.S., Pinkofsky, H.B., Liu, Y., and Bradley, R.J. (1999). Anti-
the wild-type oligo eliminated the retarded band while the mutated psychotic drugs affect glucose uptake and the expression of glu-
oligo did not (data not shown). cose transporters in PC12 cells. Prog. Neuropsychopharmacol. Biol.
Psychiatry 23, 69–80.
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